Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
LB

WKN: A42HEP | ISIN: US52886N6040 | Ticker:
NASDAQ
19.11.26 | 16:18
4,250 US-Dollar
+1,67 % +0,070
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
LEXARIA BIOSCIENCE CORP Chart 1 Jahr
5-Tage-Chart
LEXARIA BIOSCIENCE CORP 5-Tage-Chart

Aktuelle News zur LEXARIA BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:18Lexaria completes dosing in semaglutide drug delivery study5
15:02Lexaria Bioscience Corp.: Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled271KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has...
► Artikel lesen
04.11.Lexaria enters drug delivery tech agreement with pharma firm9
04.11.Lexaria Bioscience Corp.: Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH267Third pharmaceutical company relationship entered KELOWNA, BC / ACCESS Newswire / November 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery...
► Artikel lesen
28.10.Lexaria Bioscience receives four patents for drug delivery technology3
LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln
28.10.Lexaria Bioscience Corp.: Lexaria Celebrates its 70th Patent Award416New patents awarded in the US, Canada, and EuropeIP protection for treatments for Epilepsy, Diabetes, and Hypertension KELOWNA, BC / ACCESS Newswire / October 28, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)...
► Artikel lesen
21.10.Lexaria completes enrollment in semaglutide drug delivery study2
21.10.Lexaria Bioscience Corp.: Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule419KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has...
► Artikel lesen
15.10.Lexaria Bioscience Corp.: Lexaria Announces Results from Animal Study GLP-1-A26-1459Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria")...
► Artikel lesen
06.10.Lexaria Bioscience Corp.: GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications576Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS...
► Artikel lesen
17.09.Lexaria Bioscience Corp.: Lexaria Updates Financial Position477KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria...
► Artikel lesen
09.09.Lexaria Bioscience Corp.: Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds591KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced...
► Artikel lesen
09.09.Lexaria Bioscience Corp. - 8-K, Current Report4
08.09.Lexaria Bioscience announces $5.9M warrant exercise6
08.09.Lexaria Bioscience Corp.: Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds372KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced...
► Artikel lesen
04.09.Lexaria Bioscience Corp.: Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference471KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate...
► Artikel lesen
01.09.Lexaria Bioscience advances 12% on Australian tax rebate3
01.09.Lexaria receives $2.6M R&D tax rebate from Australian Tax Office; shares up over 14%2
01.09.Lexaria receives $2.6 million Australian R&D tax rebate5
01.09.Lexaria Bioscience Corp.: Lexaria Receives USD$2.6 Million Tax Rebate Payment433Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company")...
► Artikel lesen
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,3,1